Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Likun Liu

Showing results (81-90 of 86) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 86 results.
Eco-Environment & Health|August 12, 2025
Widowhood disparities in nonaccidental mortality attributable to heat waves and ozoneRuijun Xu, Yi Zheng, Jing Wei, et al.
BMJ (Clinical Research Ed.)|March 12, 2026
Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trialZhi Peng, Yanqiao Zhang, Huiting Xu, et al.
Journal of Gastrointestinal Oncology|September 12, 2022
Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: a sub-analysis from the large-scale, prospective observational study of apatinib for gastric cancer treatment in a real-world clinical setting (AHEAD-G202)Xiang Wang, Diansheng Zhong, Junping Zhang, et al.
Therapeutic Advances in Medical Oncology|March 29, 2020
An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)Xiang Wang, Ruixing Zhang, Nan Du, et al.
American Journal of Cancer Research|April 9, 2020
Safety and effectiveness of apatinib in patients with previously treated metastatic gastric cancer: a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)Xiang Wang, Junyan Yu, Mudan Yang, et al.
BMC Medicine|May 5, 2023
Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV studyJin Li, Shukui Qin, Lu Wen, et al.
Pageof 9

Showing results (81-90 of 86) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 86 results.
Eco-Environment & Health|August 12, 2025
Widowhood disparities in nonaccidental mortality attributable to heat waves and ozoneRuijun Xu, Yi Zheng, Jing Wei, et al.
BMJ (Clinical Research Ed.)|March 12, 2026
Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trialZhi Peng, Yanqiao Zhang, Huiting Xu, et al.
Journal of Gastrointestinal Oncology|September 12, 2022
Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: a sub-analysis from the large-scale, prospective observational study of apatinib for gastric cancer treatment in a real-world clinical setting (AHEAD-G202)Xiang Wang, Diansheng Zhong, Junping Zhang, et al.
Therapeutic Advances in Medical Oncology|March 29, 2020
An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)Xiang Wang, Ruixing Zhang, Nan Du, et al.
American Journal of Cancer Research|April 9, 2020
Safety and effectiveness of apatinib in patients with previously treated metastatic gastric cancer: a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)Xiang Wang, Junyan Yu, Mudan Yang, et al.
BMC Medicine|May 5, 2023
Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV studyJin Li, Shukui Qin, Lu Wen, et al.
Pageof 9